Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alfaxalone is a synthetic neuroactive steroid and general anesthetic primarily used in veterinary medicine for the induction and maintenance of anesthesia in dogs and cats. It acts as a central nervous system depressant by modulating gamma aminobutyric acid type A (GABAA) receptors in the brain. At low concentrations it positively modulates chloride current through these receptors; at higher concentrations it acts as a GABA agonist similar to barbiturates. This results in hyperpolarization of neuronal membranes and profound sedation or anesthesia depending on dose. Alfaxalone is structurally related to allopregnanolone but lacks progestogenic or endocrine hormonal activity. It has a high therapeutic index and is considered fast acting with minimal cardiorespiratory effects when used appropriately[1][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alfaxalone.